TNDM Stock Overview
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally.
Tandem Diabetes Care Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$74.71|
|52 Week High||US$155.86|
|52 Week Low||US$67.03|
|1 Month Change||-35.22%|
|3 Month Change||-36.23%|
|1 Year Change||-8.48%|
|3 Year Change||10.80%|
|5 Year Change||789.30%|
|Change since IPO||-61.21%|
Recent News & Updates
|TNDM||US Medical Equipment||US Market|
Return vs Industry: TNDM exceeded the US Medical Equipment industry which returned -15.1% over the past year.
Return vs Market: TNDM exceeded the US Market which returned -10.8% over the past year.
|TNDM Average Weekly Movement||8.1%|
|Medical Equipment Industry Average Movement||10.6%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: TNDM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: TNDM's weekly volatility (8%) has been stable over the past year.
About the Company
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company’s flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump’s software.
Tandem Diabetes Care Fundamentals Summary
|TNDM fundamental statistics|
Is TNDM overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TNDM income statement (TTM)|
|Cost of Revenue||US$343.65m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||0.092|
|Net Profit Margin||0.80%|
How did TNDM perform over the long term?See historical performance and comparison
Is Tandem Diabetes Care undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: TNDM ($74.71) is trading below our estimate of fair value ($95.69)
Significantly Below Fair Value: TNDM is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: TNDM is poor value based on its PE Ratio (810.7x) compared to the US Medical Equipment industry average (35.1x).
PE vs Market: TNDM is poor value based on its PE Ratio (810.7x) compared to the US market (15.5x).
Price to Earnings Growth Ratio
PEG Ratio: TNDM is poor value based on its PEG Ratio (17.2x)
Price to Book Ratio
PB vs Industry: TNDM is overvalued based on its PB Ratio (10.9x) compared to the US Medical Equipment industry average (2.5x).
How is Tandem Diabetes Care forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TNDM's forecast earnings growth (47.1% per year) is above the savings rate (1.9%).
Earnings vs Market: TNDM's earnings (47.1% per year) are forecast to grow faster than the US market (12.5% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: TNDM's revenue (16.1% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: TNDM's revenue (16.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TNDM's Return on Equity is forecast to be low in 3 years time (10.2%).
How has Tandem Diabetes Care performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TNDM has high quality earnings.
Growing Profit Margin: TNDM became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: TNDM has become profitable over the past 5 years, growing earnings by 43% per year.
Accelerating Growth: TNDM has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: TNDM has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16.7%).
Return on Equity
High ROE: TNDM's Return on Equity (1.3%) is considered low.
How is Tandem Diabetes Care's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: TNDM's short term assets ($818.5M) exceed its short term liabilities ($131.8M).
Long Term Liabilities: TNDM's short term assets ($818.5M) exceed its long term liabilities ($446.1M).
Debt to Equity History and Analysis
Debt Level: TNDM has more cash than its total debt.
Reducing Debt: TNDM had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: TNDM's debt is well covered by operating cash flow (34.2%).
Interest Coverage: TNDM's interest payments on its debt are not well covered by EBIT (2x coverage).
What is Tandem Diabetes Care current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TNDM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TNDM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TNDM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TNDM's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as TNDM has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Sheridan (66 yo)
Mr. John F. Sheridan has been President and Chief Executive Officer at Tandem Diabetes Care, Inc., since March 01, 2019 and served as its Chief Operating Officer and Executive Vice President since April 20...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD5.74M) is about average for companies of similar size in the US market ($USD6.90M).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
Experienced Management: TNDM's management team is considered experienced (2 years average tenure).
Experienced Board: TNDM's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: TNDM insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.1%.
Tandem Diabetes Care, Inc.'s employee growth, exchange listings and data sources
- Name: Tandem Diabetes Care, Inc.
- Ticker: TNDM
- Exchange: NasdaqGM
- Founded: 2006
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$4.603b
- Shares outstanding: 63.96m
- Website: https://www.tandemdiabetes.com
Number of Employees
- Tandem Diabetes Care, Inc.
- 11075 Roselle Street
- San Diego
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/17 00:00|
|End of Day Share Price||2022/05/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.